Tag: new treatments for carcinoid syndrome

Lexicon Headquarters

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

April 2, 2012

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

READ MORE